Treatment of Canine Osteosarcoma
Each year about 10,000 dogs in the United States, mostly of the large and giant breeds, are diagnosed with osteosarcoma (OSA), a painful bone tumor. This disease also occurs in humans, though not in such high numbers. Osteosarcoma in dogs affects primarily the long bones of the leg, but can affect bones of the spine, skull, or ribs.
"Over the last ten years there have been major advances in treatment of this disease in both species.'' said Dr. M. Joy Weinstein, assistant professor of surgery at Peon's School of Veterinary Medicine, ''but better treatment protocols are still needed. Therapy for osteosarcoma of long bones includes amputation with or without chemotherapy, or limb-sparing surgery and chemotherapy. Limb sparing surgery involves removal of the primary tumor while preserving the limb through use of a bone graft or a prosthesis. Two chemotherapy drugs that appear to be most effective in this disease are adriamycin and cisplatin. Unfortunately, at this point in time, we cannot cure the disease, but we can give the dog a good quality of life for a number of months or years."
Dr. Weinstein, who returned to Penn after surgical specialty training at Tufts University School Weinstein's preferred surgical treatment. "It relieves the pain and the dog can get around quite well on three legs," she explained. ''Most dogs walk one day after surgery and need exercise restrictions for only about LWO weeks." An alternative to amputation is limb sparing surgery. She recommends this treatment for dogs that would not get around well on three legs or those cases where an owner cannot accept amputation as an option for the dog. Here the tumor and the affected section of bone are removed� and a bone graft is used to replace the missing bone. The graft can be donor bone which has beeu frozen and stored, but infections are common with this method. Dr. Mark Cofone and Dr. David Diefenderfer have used autogenous, cancellous bone as the graft. Small amounts of the soft bone from the marrow cavity of the dog's own shoulder (proximal humerus), pelvis (ilium) or knee (proximal tibia) are used to replace the diseased bone. Plates and screws hold the bones in their proper orientation. It is complicated surgery and the time period until the bone graft has healed may be several months. Limb-sparing surgery is most successful for tumors of the distal radius (lower foreleg) because the carpal joint (wrist) can be fused without problems.
Previously described chemorherapy treatment protocols for OSA incorporate cisptatin and/or adriamycin, usually given at three week intervals. The drugs are administered intravenously. They are both potent drugs that act on cell division. four dogs 1 rea ted are doing well six to ten months after Lreatment. She proposes to use the drugs postoperatively, beginning two weeks after surgery, in one group of patiems for a total of three cydes, three weeks apan. In another group of patients, the first dose of drugs wm be administered perioperatively, within 14 hours after surgery, followed by two additional treatments three weeks apart. "Studies in humans and rodents have shown that there is rapid growth of metastatic lesions in these species following surgical excision of primary tumors," she srud. "Studies in laboratory animal tumor models show that administration of peri operative chemotherapy prevents a rapid growth phase in metastatic lesions following removal of the p rimary tumor.'' Dr. Wdnstein explained that perioperative chemotherapy is not routinely administered to humans with the disease due to fear of postoperative surgical wound complications, such as infections and delayed wound healing. "Our previous results administering pre-, perioperative and postoperative adriamycin to dogs with osteosarcoma do not support high wound complication rates. We hope to document improved survival rates for patients treated with perioperative chemotheupy; this woul.d advance canine osteosarcoma treatment and might also encourage similar studies in human patients with the disease.'' Osteosarcoma in people is ad isease of teenagers and young adults. In dogs it affects primarily middle-aged animaJs, though it does occur in dogs under two years of age and in elderly dogs. Canine osteosarcoma may serve as a model for human osteosarcoma and Dr. Weinstein is collaborating with researchers at the Medical SchooJ on several projects. "We are looking at MRL images of the amputated canine limb to establish how the tumor margins seen on the image correspond to the tumor margins established by histological examination." she explained. "lt is very difficult for the surgeon, when doing limb-sparing surgery on people or dogs, to know eJCact!y where the l umor ends," she said.
"We hope to determine jusl how accurate the MRI scan is In defining the tumor margins." The studies also encompass a look at the role of growth factors and their receptors in canine osteosarcoma. The role of P-glycoprotein in the resistance of canine osteosarcoma to chemot, herapy will be investigated. The researchers hope to expand the project so that they can evaluate different clinical protocols in dogs with osteosarcoma and assess prognostic indicators and chemosensitivity assays to predict differences in the response to treatment.
nr. Weinstein is currently searching for funding for the chemotherapy study from private sources or foundations to support the costs of the drugs. Without support, surgery and the chemotherapy drugs cost about $2,000 per patient. If support can be found, Lhese costs to the clients will decrease considerably. Dr. Weinstein is also looking for candidates for the treatment and she hopes that veterinarians with canine osteosarcoma patients will refer them to the Veterinary Hospital of the University of Pennsylvania. 
